Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Mitchell Launches New Image Viewer for Mitchell SmartAdvisor Platform and Mitchell Claims Examiner Portal
New image viewer improves time to open images related to medical bills.
Mitchell Announces Enhanced AutocheX Digital Services Through Collaboration with UpdatePromise
New offerings include enhanced CSI surveys, repair status messaging and online reputation management for collision repairers.
Specialty Medication Trends
Specialty medications, which are typically used to treat patients with complex, chronic conditions, continue to be a major area of pharmaceutical development and can have significant costs.
WorkCompWire: Ensuring Seamless Ancillary Services for Catastrophic Claims
In workers' compensation, catastrophic claims often require a significant number and various types of ancillary services, anything from a rehabilitation facility, DME, transportation, home health services and more.
Risk & Insurance: Top 10 Lessons Learned in Helping Workers Move Past COVID-19
Here are the top lessons workers' comp pros have learned about COVID-19, its impact on the workplace and on how to help employees get back to
2021 Regulatory Predictions for Auto Casualty and Workers’ Comp [Podcast]
In 2020, the workers' compensation and auto casualty regulatory environment was more active than ever—since the start of the COVID-19 pandemic, U.S